-
JAMA Neurology Oct 2018
Topics: Humans; Immunization, Passive; Parkinson Disease; alpha-Synuclein
PubMed: 29913004
DOI: 10.1001/jamaneurol.2018.0346 -
Sub-cellular Biochemistry 2019Monoclonal based therapeutics have always been looked at as a futuristic natural way we could take care of pathogens and many diseases. However, in order to develop,... (Review)
Review
Monoclonal based therapeutics have always been looked at as a futuristic natural way we could take care of pathogens and many diseases. However, in order to develop, establish and realize monoclonal based therapy we need to understand how the immune system contains or kill pathogens. Antibody complexes serve the means to decode this black box. We have discussed examples of antibody complexes both at biochemical and structural levels to understand and appreciate how discoveries in the field of antibody complexes have started to decoded mechanism of viral invasion and create potential vaccine targets against many pathogens. Antibody complexes have made advancement in our knowledge about the molecular interaction between antibody and antigen. It has also led to identification of potent protective monoclonal antibodies. Further use of selective combination of monoclonal antibodies have provided improved protection against deadly diseases. The administration of newly designed and improved immunogen has been used as potential vaccine. Therefore, antibody complexes are important tools to develop new vaccine targets and design an improved combination of monoclonal antibodies for passive immunization or protection with very little or no side effects.
Topics: Antibodies, Monoclonal; Antigen-Antibody Complex; Humans; Immunization, Passive
PubMed: 31939148
DOI: 10.1007/978-3-030-28151-9_2 -
Expert Opinion on Biological Therapy Apr 2009Passive immunization strategies are under investigation as potential disease-modifying therapies for Alzheimer's disease (AD). Current approaches, based on data... (Review)
Review
BACKGROUND
Passive immunization strategies are under investigation as potential disease-modifying therapies for Alzheimer's disease (AD). Current approaches, based on data demonstrating behavioral improvement and reduced pathology in transgenic animal models, have focused exclusively on immune targeting of beta-amyloid.
OBJECTIVE
To examine immunization strategies for AD.
METHODS
A review of relevant publications.
RESULTS/CONCLUSIONS
Preliminary results from three Phase II trials suggest both the promise and the need to exercise caution with this method of immunotherapy. The strategies used were distinct, using monoclonal N-terminal, central epitope, and polyclonal antibodies to maximize the efficacy and safety of each approach. The tested compounds are moving into Phase III trials for mild to moderate AD. We await the discoveries that from these studies that may yield the first disease-modifying therapy for AD.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Clinical Trials as Topic; Humans; Immunization, Passive
PubMed: 19344284
DOI: 10.1517/14712590902828285 -
The Journal of Allergy and Clinical... Dec 2021
Topics: Administration, Oral; Adoptive Transfer; Animal Feed; Animals; Biological Products; Birds; Cats; Immunization, Passive; Immunoglobulin E; Immunoglobulins
PubMed: 34530018
DOI: 10.1016/j.jaci.2021.06.031 -
Annual Review of Immunology Apr 2022Antibodies have been used to prevent or treat viral infections since the nineteenth century, but the full potential to use passive immunization for infectious diseases... (Review)
Review
Antibodies have been used to prevent or treat viral infections since the nineteenth century, but the full potential to use passive immunization for infectious diseases has yet to be realized. The advent of efficient methods for isolating broad and potently neutralizing human monoclonal antibodies is enabling us to develop antibodies with unprecedented activities. The discovery of IgG Fc region modifications that extend antibody half-life in humans to three months or more suggests that antibodies could become the principal tool with which we manage future viral epidemics. Antibodies for members of most virus families that cause severe disease in humans have been isolated, and many of them are in clinical development, an area that has accelerated during the effort to prevent or treat COVID-19 (coronavirus disease 2019). Broad and potently neutralizing antibodies are also important research reagents for identification of protective epitopes that can be engineered into active vaccines through structure-based reverse vaccinology.
Topics: Animals; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; Epitopes; Humans; Immunization, Passive
PubMed: 35113730
DOI: 10.1146/annurev-immunol-042718-041309 -
Neurobiology of Disease Oct 2019Active and passive immunization have been used to treat human disease for hundreds of years and improvements in technology and knowledge is only increasing the number of... (Review)
Review
Active and passive immunization have been used to treat human disease for hundreds of years and improvements in technology and knowledge is only increasing the number of therapeutic applications. The current and future use of immunization to treat neurodegenerative diseases are briefly described herein to serve as an introduction to this special issue.
Topics: Humans; Immunization, Passive; Neurodegenerative Diseases; Vaccination
PubMed: 31216439
DOI: 10.1016/j.nbd.2019.104504 -
Annual Review of Food Science and... 2012The avian egg contains all of the necessary nutrients and growth factors required for the developing embryo, including antibodies that are transported from the blood of... (Review)
Review
The avian egg contains all of the necessary nutrients and growth factors required for the developing embryo, including antibodies that are transported from the blood of the hen into the egg yolk to provide immunity to the chick. Since the discovery of egg yolk antibodies, now called immunoglobulin Y (IgY), in the late 1800s, this process has been harnessed to produce antigen-specific yolk antibodies for numerous applications in the medical and research fields, including in areas such as diagnostics and proteomics. However, one of the most valuable and promising areas of IgY research is its use for passive immunization to treat and prevent human and animal diseases. The following review covers the key features and advantages of IgY and the production and purification of IgY from the egg yolk, as well as highlights some of the most promising applications of egg yolk antibodies in human and veterinary medicine.
Topics: Animals; Avian Proteins; Chickens; Egg Yolk; Female; Humans; Immunization, Passive; Immunoglobulins
PubMed: 22136128
DOI: 10.1146/annurev-food-022811-101137 -
The Lancet. Infectious Diseases May 2012Prevention of clinical disease in those exposed to viral infection is an important goal of human medicine. Using rabies virus infection as an example, we discuss the... (Review)
Review
Prevention of clinical disease in those exposed to viral infection is an important goal of human medicine. Using rabies virus infection as an example, we discuss the advances in passive immunoprophylaxis, most notably the shift from the recommended polyclonal human or equine immunoglobulins to monoclonal antibody therapies. The first rabies-specific monoclonal antibodies are undergoing clinical trials, so passive immunisation might finally become an accessible, affordable, and routinely used part of global health practices for rabies. Coupled with an adequate supply of modern tissue-culture vaccines, replacing the less efficient and unsafe nerve-tissue-derived rabies vaccines, the burden of this disease could be substantially reduced.
Topics: Antibodies, Monoclonal; Antibodies, Viral; Humans; Immunization, Passive; Immunoglobulins; Rabies
PubMed: 22541629
DOI: 10.1016/S1473-3099(11)70340-1 -
Human Vaccines & Immunotherapeutics Dec 2020Passive immunotherapeutics (PITs), including convalescent plasma, serum, or hyperimmune immunoglobulin, have been of clinical importance during sudden outbreaks since... (Review)
Review
Passive immunotherapeutics (PITs), including convalescent plasma, serum, or hyperimmune immunoglobulin, have been of clinical importance during sudden outbreaks since the early twentieth century for the treatment of viral diseases such as severe acute respiratory syndrome (SARS), middle east respiratory syndrome (MERS) and swine flu (H1N1). With the recent SARS-CoV-2 pandemic, wherein effective antivirals and vaccines are still lacking, an interest in convalescent plasma therapy as a lifesaving option has resurfaced due to its capacity for antigenic neutralization and reducing viremia. This review summarizes convalescent blood products (CBPs) in terms of current technologies and the shortcomings related to the collection, manufacture, pathogen inactivation, and banking of CBPs, with a specific focus on their plausible applications, benefits, and risks in the COVID-19 pandemic.
Topics: COVID-19; Humans; Immunization, Passive; Risk Assessment; COVID-19 Serotherapy
PubMed: 32962524
DOI: 10.1080/21645515.2020.1808410 -
Annals of Internal Medicine Mar 1970
Topics: Adult; Humans; Immunization, Passive; Immunotherapy; Male; Military Medicine; Rabies; Rabies Vaccines; United States; Vietnam
PubMed: 5415426
DOI: 10.7326/0003-4819-72-3-435_1